About OliX Pharmaceuticals
OliX Pharmaceuticals is a company based in Suwon (South Korea) founded in 2010.. The company has 69 employees as of December 31, 2024. OliX Pharmaceuticals operates in a competitive market with competitors including Avidity Biosciences, Alnylam, Dicerna Pharmaceuticals, Silence Therapeutics and Sirnaomics, among others.
- Headquarter Suwon, South Korea
- Employees 69 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Olix Pharmaceuticals, Inc.
-
Annual Revenue
$3.85 M (USD)-66.73as on Dec 31, 2024
-
Net Profit
$-27.57 M (USD)-112.85as on Dec 31, 2024
-
EBITDA
$-19.18 M (USD)-82.02as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
69
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of OliX Pharmaceuticals
OliX Pharmaceuticals is a publicly listed company on the KRX with ticker symbol 226950 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Funding Insights of OliX Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by OliX Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - OliX Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Olix Pharmaceuticals Comparisons
Competitors of OliX Pharmaceuticals
OliX Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Alnylam, Dicerna Pharmaceuticals, Silence Therapeutics and Sirnaomics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Drugs are developed using RNA interference technology platform.
|
|
| domain | founded_year | HQ Location |
RNA therapeutics for hematology and cardiovascular diseases are developed.
|
|
| domain | founded_year | HQ Location |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| domain | founded_year | HQ Location |
RNAi therapeutics for neurodegenerative diseases are developed using branched siRNA.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Olix Pharmaceuticals
Frequently Asked Questions about OliX Pharmaceuticals
When was OliX Pharmaceuticals founded?
OliX Pharmaceuticals was founded in 2010.
Where is OliX Pharmaceuticals located?
OliX Pharmaceuticals is headquartered in Suwon, South Korea. It is registered at Suwon, Gyeonggi, South Korea.
How many employees does OliX Pharmaceuticals have?
As of Dec 31, 2024, the latest employee count at OliX Pharmaceuticals is 69.
What is the annual revenue of OliX Pharmaceuticals?
Annual revenue of OliX Pharmaceuticals is $3.85M as on Dec 31, 2024.
What does OliX Pharmaceuticals do?
Developer of RNAi therapeutics for dermal, ophthalmic, and pulmonary diseases. Its drug pipeline includes OLX101 for the treatment of Skin Scar (licensed out to Huge Inc.), OLX201 for the treatment of Lung fibrosis, OLX301 for the treatment of Wet AMDRetinal Fibrosis, OLX701 for liver fibrosis. Other products include OLX102 for skin whitening and OLX105 to get rid of wrinkles. The companys technology is based on three types of RNA: Small interfering RNA (siRNA), Asymmetric siRNA (siRNA), and Cell-penetrating asymmetric siRNA (cp-siRNA).
Who are the top competitors of OliX Pharmaceuticals?
OliX Pharmaceuticals's top competitors include Alnylam, Avidity Biosciences and Silence Therapeutics.
Is OliX Pharmaceuticals publicly traded?
Yes, OliX Pharmaceuticals is publicly traded on KRX under the ticker symbol 226950.
What is OliX Pharmaceuticals's ticker symbol?
The ticker symbol of OliX Pharmaceuticals is 226950 on KRX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.